Shire faces criticism on CEO pay policy as crunch week looms

LONDON, April 18 (Reuters) - Shire, the $47 billion rare disease drugmaker being stalked by Japan's Takeda Pharmaceutical, faces fresh criticism over its executive pay policy from a leading investor advisory group as a crunch week approaches.